slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 205,861-205,890
Pages 10,126
Rows per page 30
Component
205,861-205,890 of 303,780
87
The chart shows a 38% CAGR for partnership revenue from 2022 to 2025.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
88
The slide uses bar charts for revenue and gross profit, and a combination bar/line chart for cash and free cash flow.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
89
The slide combines a quadrant-based strategy overview with a waterfall bridge chart.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
90
Berkeley Lights | Investor Day Presentation Deck | 91 slidesBerkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
91
Berkeley Lights | Investor Day Presentation Deck | 91 slidesBerkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
01
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
02
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
03
The slide uses a connected circle diagram to represent the company's key pillars.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
Uses a visual comparison framework to contrast healthy cells (no binding) vs cancer cells (binding).BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
The slide uses a Gantt-style visualization to show the clinical stage of drug candidates.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
08
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
09
The slide uses a structured list format to contrast the specific opportunity in UPS with the broader landscape of other sarcoma subtypes.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · Market Size1 hit
10
Includes waterfall plot for partial response and spider plot for longitudinal tumor change.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
11
The slide uses a hierarchical tree structure to map patient cohorts to their respective clinical outcomes and advancement decisions.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
12
Includes 'Number at Risk' table below the Kaplan-Meier plot.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
The slide uses a 2x2 grid of metrics to frame the market opportunity, followed by specific target population and success threshold data.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
The chart displays maximum change from baseline for four distinct patient cohorts/scenarios.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
The slide uses a process-oriented layout to describe clinical trial phases.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
Waterfall plot showing clinical response (PD, SD, PR, CR) for patients treated with BA3011.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
21
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
22
The slide uses a grid of metrics to define the addressable market and clinical success thresholds.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
23
The chart is a waterfall plot showing percentage change in tumor size for individual patients.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
24
The slide uses a 2x2 grid of metrics to frame the market problem, followed by specific target population sizing.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
26
The slide uses a combination of big numbers and bulleted lists to frame the market opportunity and clinical unmet need.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
27
The slide uses a table to present clinical outcomes (PR/CR) for specific tumor types, supporting the 'first-in-class' claim.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
28
The slide uses a process-flow layout to describe clinical trial progression.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
29
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
31
The slide uses a timeline-based visualization to show dose escalation steps. RP2D = Recommended Phase 2 Dose. DLT = Dose Limiting Toxicity.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit